GSK plans to divest non-core OTC brands in an effort to focus on its Consumer Healthcare business around a portfolio of priority brands and emerging markets. The focus will be on three categories: Oral Health, Wellness/OTC and Nutrition, with brands such as Sensodyne, Panadol and Horlicks. The company hopes to divest the products by late 2011. The products to be divested, which are primarily sold in Europe and the U.S., include analgesics such as Solpadeine, BC and Goody’s, vitamin and supple...